Latest filingSep 08, 2026Most recent Form 4
RGEN
REPLIGEN CORP
NasdaqHealthcareBiological Products, (No Diagnostic Substances)
Insider activity for last month from 08/09 to 09/09. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total buying$00 buys
Total selling$148M2 sells
Net open-market-$148M2 insiders
Open-market mix
Buy vs sell distribution by transaction countInsider activity report
Monthly open-market purchase and sale counts Buys Sells
Transaction codes
By Form 4 transaction code in selected period6transactions
- F · Tax withholding · dominant2 · 33%
- M · Option exercise2 · 33%
- S · Open-market sells2 · 33%
Activity by reported role
A joint filing can contribute to multiple roles6transactions
- Chief executive officer · dominant5 · 83%
- CAO1 · 17%
Distinct insiders active
Reporting-owner CIKs by month · peak Sep 2026 (2)Aug 2026Sep 2026
Reported Holdings After
Separated by insider, security, and ownership typeLoeillot OlivierCommon Stock · Direct
48,369Sep 04, 2026
Loeillot OlivierStock Option (Right to Buy) · Direct
10,852Aug 20, 2026
Hughes ViolettaCommon Stock · Direct
6,331Sep 01, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells redAug 09 → Sep 09
LessMore
Top insiders
By absolute net value across the selected period- LO-$1.2M
- HV-$47.1k
Filing detail checks
Secondary metrics for the selected periodFiling-only signals
Deterministic matches in the selected period
RGEN transaction history
Filters apply within this company and selected period by default| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| RGEN | Loeillot Olivier | CEO | sale10b5-1 | 3.03k | -$50.3M | S | — | 0.0% | 09/08 | 09/04 |
| RGEN | Loeillot Olivier | CEO | withholding10b5-1 | 2.84k | -$48.2M | F | — | 0.0% | 09/08 | 09/03 |
| RGEN | Hughes Violetta | CAO | withholding | 277 | -$4.70M | F | — | 0.0% | 09/02 | 09/01 |
| RGEN | Loeillot Olivier | CEO | exercise10b5-1 | 5.42k | $0 | M | −2.7% | 08/21 | 08/20 | |
| RGEN | Loeillot Olivier | CEO | sale10b5-1 | 5.42k | -$97.6M | S | −2.7% | 08/21 | 08/20 | |
| RGEN | Loeillot Olivier | CEO | exercise10b5-1 | 5.42k | $76.9M | M | −2.7% | 08/21 | 08/20 |
REPLIGEN CORP Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at REPLIGEN CORP?
Loeillot Olivier, Hughes Violetta.
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
Loeillot Olivier reported a sale on Sep 04, 2026 valued at $50.3M. Read the SEC filing.
What is the recent purchase and sale balance?
Net open-market selling in the selected period was $1,480,186.50. Sales can occur for many non-investment reasons.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.